Skip links
OncoOne

OncoOne Celebrates its 5th Anniversary.

It is hard to believe how time flies, and that OncoOne already celebrated its 5th anniversary last month. Together with our team, we took this opportunity to commemorate this amazing accomplishment. In just 5 years, we have raised €18M in funding from private investors and

60TH ERA Congress, June 15-18, 2023, Milan, IT

We are proud to announce that Christine Landlinger-Schubert, our VP of Preclinical and Translational R&D, will be delivering a Focused Oral presentation at the ERA Congress held from June 15-18 in Milan, Italy. Christine’s presentation titled “ON104: A novel bioengineered antibody targeting oxidized Macrophage Migration

BIO International Convention, June 5-8, 2023, Boston, MA, US

OncoOne’s CEO, Randolf Kerschbaumer, will be attending the BIO International Convention in Boston from June 5-8! With a projected 44,000+ meetings scheduled over four days, we can’t wait to connect with like-minded companies who share our passion for science.

PEGS 2023 Boston, May 15-19, 2023, Boston, MA, US

Join our CTO Alexander Schinagl at PEGS Boston. OncoOne is excited to present our latest research on “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer” at PEGS23. The study highlights the potential of our innovative PreTarg-it® platform combining a bispecific

Bio€quity 2023, May 14-16, 2023, Dublin, IR

OncoOne’s CSO, Michael Thiele, will be attending #BIOEQUITY in Dublin from May 14-16! This is a great opportunity to connect with us and discuss potential collaborations to advance our innovative research in oncology and inflammation therapies to the clinic.

BIO Asia Partnering Forum, April 26-27, 2023, Singapore, SG

Delighted to announce that OncoOne’s CEO, Randolf Kerschbaumer, will be attending BIO Asia Partnering Forum ASIABIO, held in Singapore April 26-27! Join us as he presents our latest developments in our oxMIF targeted pipeline for cancer and inflammation.

OncoOne Presents Preclinical Data Update from oxMIF-targeting Pipeline including ON203 and PreTarg-it ® ON-05 at the 2023 AACR Annual Meeting

PDF – Next-generation anti-oxMIF antibody ON203 demonstrates anti-tumor effects through tumor cell death and modulation of the immunosuppressive tumor microenvironment in human tumoroids isolated from colorectal adenocarcinoma patients.– First preclinical data from OncoOne’s PreTarg-it® platform show significant tumor regression and survival benefit in models of

AACR Annual Meeting, April 14-19, 2023, Orlando, FL, US

Meet with our CTO Alexander Schinagl and CBO Brent Meadows at our two posters entitled: Poster #2974 “Targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) with antibody ON203 activates the tumor microenvironment” and Poster #585 “Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody
Home